

12-23-05  
AP4 Rec'd PCT/PTO 22 DEC 2005

10/562021 PATENT



Attorney Docket No. 10340.204-US

IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

INTERNATIONAL APPLICATION NO.: PCT/DK2004/000468

INTERNATIONAL FILING DATE: July 1, 2004

PRIORITY DATE: July 1, 2003

TITLE: CGTase Variants

APPLICANT(S) FOR RO/US: Svendsen et al.

**EXPRESS MAIL CERTIFICATE**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Express Mail Label No. **EV 138338541 US**

Date of Deposit: December 22, 2005

I hereby certify that the following attached papers or fee

1. Transmittal Letter to the DO/EO/US (in duplicate)
2. Application Data Sheet
3. Preliminary Amendment
4. Paper Copy of Sequence Listing
5. Disk Containing Sequence Listing
6. Information Disclosure Statement
7. Form PTO/SB/08A
8. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the address indicated above.

Julie Tabarovsky

(Name of person mailing paper(s) or fee)

(Signature of person mailing paper(s) or fee)

Mailing Address:

Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**10/562021****IAP20 Rec'd PCT 22 DEC 2005**  
**PATENT**

Attorney Docket No.: 10340.204-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE****TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE  
(DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is a request for filing a patent application under 35 U.S.C. 371 of the international application identified below:

INTERNATIONAL APPLICATION NO. PCT/DK2004/000468		INTERNATIONAL FILING DATE July 1, 2004
<b>APPLICANT(S)/INVENTOR(S)</b>		
First Name	Middle Name	Family Name
1.Allan 2.Lars 3.Tina 4.Morten 5.Christel	1. 2. 3. 4.Tovborg 5.Thea	1.Svensden 2.Beier 3.Spendler 4.Jensen 5.Jorgensen
<b>TITLE OF THE INVENTION</b>		
CGTase Variants		

1. This is a first submission of items concerning a filing under 35 U.S.C. 371.
2. This is an express request to begin national examination procedures (35 U.S.C. 371(f)).
3. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) has been communicated by the International Bureau The application contains the following parts:

Specification	15 Pages
Abstract	1 Pages
Sequence Listing	10 Pages
Drawings	7 Pages
Total	33 Pages

4. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.
5. An application data sheet is enclosed.
6. Priority of Danish application no. PA 2003 00994 filed on July 1, 2003 is claimed under 35 U.S.C. 119(a)-(d).

7. The benefit of U.S. provisional application no. 60/484,004 filed on July 1, 2003 is claimed under 35 U.S.C. 119(e).
8. An Information Disclosure Statement is submitted herewith.
9. A Preliminary Amendment is submitted herewith.
10. Applicants enclose a paper copy and a computer readable form of a Sequence Listing. The content of the paper copy and of the computer readable form is the same.
11. The assignee of the present application is:

Novozymes A/S  
Krogshoejvej 36  
DK-2880 Bagsvaerd  
Denmark

Applicants request that the assignee information be included in the published patent application.

12. Direct all correspondence to Customer Number 25908.
13. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):

Basic Fee:	\$300.00
Examination Fee:	\$200.00
Search Fee:	\$500.00
Size Fee (\$250 for each 50 pages above 100)	\$0.00

CLAIMS FEE

Total Claims: $14 - 20 = 0 \times 50 =$	\$0.00
Independent Claims: $3 - 3 = 0 \times 200 =$	\$0.00
Total Claims Fee:	\$0.00

TOTAL NATIONAL FEE	\$1,000.00
--------------------	------------

14. Please charge the required fee, estimated to be \$1,000, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: December 22, 2005

  
Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097